Effects of clopidogrel and proton pump inhibitors on cardiovascular events in patients with type 2 diabetes mellitus after drug-eluting stent implantation: A nationwide cohort study

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Hsieh, Chi Feng ^a   Huang, Weng Foung ^a   Chiang, Yi Ting ^a   Chen, Chun Yen ^b,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c MACKAY MEDICAL COLLEGE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PROTON PUMP INHIBITOR; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DRUG ELUTING CORONARY STENT; FEMALE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PACLITAXEL ELUTING CORONARY STENT; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; TAIWAN; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPLICATION; CORONARY ARTERY BYPASS GRAFT; DRUG ELUTING STENT; RISK FACTOR;

ACUTE CORONARY SYNDROME; AGED; CORONARY ARTERY BYPASS; DIABETES MELLITUS, TYPE 2; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; TICLOPIDINE;

EID: 84943278807     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135915     Document Type: Article

References (34)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502. PMID: 11519503
2. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. Jama. 2002;288(19):2411-20. PMID: 12435254
3. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527-33. PMID: 11520521
4. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370(9591):937-48. PMID: 17869634
5. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47(10):2108-11. PMID: 16697331
6. Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014;46(4):517-92. doi: 10.1093/ejcts/ezu366 PMID: 25173601
7. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105(12):2533-49. doi: 10. 1038/ajg.2010.445 PMID: 21131924
8. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J AmColl Cardiol. 2008;52(18):1502-17. doi: 10.1016/j.jacc.2008.08.002 PMID: 19017521
9. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):e1-e157. PMID: 17692738
10. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008;52(12):1038-9; author reply 1039. doi: 10. 1016/j.jacc.2008.05.053 PMID: 18786491
11. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. Jama. 2009;301(9):937-44. doi: 10.1001/jama.2009.261 PMID: 19258584
12. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Cmaj. 2009;180(7):713-8. doi: 10. 1503/cmaj.082001 PMID: 19176635
13. Huang CC, Chen YC, Leu HB, Chen TJ, Lin SJ, Chan WL, et al. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol. 2010;105(12):1705-9. doi: 10.1016/j.amjcard.2010. 01.348 PMID: 20538118
14. Wu CY, Chan FK, Wu MS, Kuo KN, Wang CB, Tsao CR, et al. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology. 2010;139(4):1165-71. doi: 10.1053/j.gastro.2010.06.067 PMID: 20600012
15. Lin CF, Shen LJ, Wu FL, Bai CH, Gau CS. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. Br J Clin Pharmacol. 2012;74(5):824-34. doi: 10.1111/j.1365-2125.2012.04250.x PMID: 22364155
16. Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, et al. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). JACC Cardiovasc Interv. 2013;6(12):1275-81. doi: 10.1016/j.jcin. 2013.06. 014 PMID: 24239201
17. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. The New England journal of medicine. 2010;363(20):1909-17. doi: 10.1056/NEJMoa1007964 PMID: 20925534
18. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. Journal of Clinical Epidemiology. 1993;46(10):1075-9. PMID: 8410092
19. Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health. 2000;21:121-45. PMID: 10884949
20. Stockl KM, Le L, Zakharyan A, Harada AS, Solow BK, Addiego JE, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010;170(8):704-10. doi: 10. 1001/archinternmed.2010.34 PMID: 20421557
21. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51(3):256-60. doi: 10.1016/j.jacc.2007.06. 064 PMID: 18206732
22. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmöller J. Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs. Clinical pharmacokinetics. 2005;44(12):1209-25. PMID: 16372821
23. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-offunction polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244-7. PMID: 16772608
24. Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ, et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother. 2009;63(5):1017-24. doi: 10.1093/jac/dkp034 PMID: 19246508
25. Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109(25):3171-5. PMID: 15184279
26. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009;53(10):849-56. doi: 10.1016/j.jacc.2008.11.030 PMID: 19264241
27. Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P, et al. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol. 2010;56(25):2084-9. doi: 10.1016/j.jacc.2010.10.006 PMID: 21144968
28. StoneGW, Kedhi E, Kereiakes DJ, Parise H, Fahy M, Serruys PW, et al. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation. 2011;124(8):893-900. doi: 10.1161/CIRCULATIONAHA.111.031070 PMID: 21824922
29. Kufner S, Byrne RA, de Waha A, Schulz S, Joner M, Laugwitz KL, et al. Sirolimus-eluting versus paclitaxeleluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial. Cardiovasc Revasc Med. 2014;15(2):69-75. doi: 10.1016/j. carrev. 2014.02.001 PMID: 24684757
30. Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2009;103(10):1339-43. doi: 10.1016/j.amjcard.2009.01.341 PMID: 19427425
31. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29(8):992-1000. doi: 10.1093/eurheartj/ehn046 PMID: 18263931
32. Camici GG, Steffel J, Amanovic I, Breitenstein A, Baldinger J, Keller S, et al. Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. Eur Heart J. 2010;31(2):236-42. doi: 10.1093/eurheartj/ehp259 PMID: 19567381
33. Jiang P, Lan Y, Luo J, Ren YL, Liu DG, Pang JX, et al. Rapamycin promoted thrombosis and platelet adhesion to endothelial cells by inducing membrane remodeling. BMC Cell Biol. 2014;15:7. doi: 10. 1186/1471-2121-15-7 PMID: 24564184
34. Lee JJ, Yu JY, Lee JH, Zhang WY, Kim TJ, Myung CS, et al. The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase. Arch Pharm Res. 2010;33(3):387-94. doi: 10.1007/s12272-010-0307-1 PMID: 20361303